Opioids are a class of drugs which are largely used for relieving pain. One of the first opioid drugs ‘morphine’ was developed in 1803. Opioid drugs act on the opioid receptors present in the central and peripheral nervous system thus providing relief from pain. Opioid are administered in the form of as oral pills, parenteral, liquids, patches or lozenges. There are different types of prescription opioids available such as fentanyl, oxycodone, morphine, codeine, oxymorphone, and hydrocodone which are prescribed by physicians for treating pain.
Market Dynamics
Increasing R&D in synthesis of hybrids targeting opioid and neurokinin receptors is expected to offer lucrative growth opportunities for market players. For instance, in December 2019, researchers from Medical University of Lodz reported the synthesis, structure–activity relationship, and pharmacological characterization of a series of hybrids combining opioid pharmacophores with either substance P (SP) fragments or neurokinin receptor (NK1) antagonist fragments in order to comprehend the role of the neurokinin system in opioid-induced antinociception.
Key players in the market are focused on product approvals and launches to expand their product portfolio. For instance, in June 2018, AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company received the European Commission (EC) approval for DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. The market is witnessing increasing merger and acquisition activities. For instance, Grünenthal acquired the U.S.-based pharmaceutical company ‘Averitas Pharma’ in order to expand its presence in the U.S.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook